WiSys Technologies

11 WiSys Technologies in "Miscellaneous" or "Pharmaceuticals & Vitamin D"

Fully-Customizable Beverage Mixing

WiSys is seeking a strategic industry partner for further development, manufacturing, sales, and distribution of this technology, which allows the user to customize the relative proportions of liquids in a mixed beverage.

Physics ‘Office Hours’ educational learning platform

WiSys Technology Foundation is seeking a commercial partner who is interested in licensing and distributing an educational app focused on Physics, expanding the platform beyond Android applications as well as further developing additional apps directed towards other STEM disciplines.

Saddle Lift to Enhance Independence of Horseback Riders with Disabilities

WiSys Technology Foundation is seeking a strategic partner for manufacturing, marketing, sales, and distribution of a lift that allows para-equestrian riders to independently saddle their horses.

Novel Waterfowl Decoy Design with Natural Motion Technology

WiSys is currently seeking a strategic partner interested in expanding their existing product line of waterfowl and/or game bird decoys. By accessing WiSys’ patent pending technology and prototype design, companies are provided with an exclusive opportunity to enhance their competitive position in the motion decoy space and compete with existing products on the market by providing their customers with a more realistic waterfowl decoy with natural motion.

Skin Whitening Agent(s)

WiSys Technology Foundation is currently seeking a strategic industry partner to assist in the further development of its lead compound, A11, and related analogues providing a route to market for their use as novel skin whitening/lightening agents.The competitive advantage of these compounds over existing agents on the market is that they produce long-acting and reversible skin lightening with no toxicity.

Benzodiazepine Derivatives with Reduced Side Effects

The WiSys Technology Foundation is seeking commercial partners interested in developing anxiolytic and anticonvulsant benzodiazepines that offer little or no side effects.